Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries
Article in BMC Health Services Research (November 2022)
The most recent citing publications are shown below. View all 20 publications that cite this research output on Dimensions.
Article in BMC Health Services Research (November 2022)
Article in Inflammatory Bowel Diseases (August 2022)
Preprint in Research Square (February 2022)